US FDA's inaugural biosimilar review bumpier than first appeared
This article was originally published in SRA
Executive Summary
Sue Sutter explains how the US Food and Drug Administration's handling of issues around protein content differences, statistical analyses of quality data and immunogenicity testing for Sandoz's Zarxio may prove instructive for future 351(k) applicants.
You may also be interested in...
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
FDA says problem with protein misfolding with Sandoz' Enbrel biosimilar candidate unlikely to generate unique toxicity issues in extrapolated indications.
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
FDA says Sandoz's biosimilar is highly similar to Amgen's Enbrel after Sandoz answered question about data comparing it to US-approved product.
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
FDA says Sandoz's biosimilar is highly similar to Amgen's Enbrel after Sandoz answered question about data comparing it to US-approved product.